ClinicalTrials.gg
Status unknownNCT04985786PathRiskUpdated Aug 11, 2021

Dynamics of Risk Perception and Risk Behavior in Alcohol Use Disorder and Schizophrenia

An interventional study of Cognitive Behavioral Therapy for reducing risk behaviors and Cognitive Behavioral Therapy for increasing non-risk behaviors in Alcohol Use Disorder (AUD) and Schizophrenia and Related Disorders, sponsored by University of Konstanz. Status unknown at 1 site in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-11.

Sponsored by University of Konstanz · Not applicable, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Aug 2021), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The hyper- or hypo-attribution of risks is deeply related to the core pathological mechanisms of mental disorders and at the same time engaging in risky behaviors influences their course and outcomes. The investigators study risk perception, risk behaviors and underlying brain mechanisms in a longitudinal design in three groups of psychiatric patients who participate in a psychological intervention that is aimed to reduce risk behavior and increase risk perception.

Patients with schizophrenia (SZ), alcohol use disorder (AUD) and both disorders (SZ + AUD) are recruited during psychiatric in-patient treatment and participate in a combined face-to-face and mobile intervention that starts before release and ends four weeks after discharge. The standardized 4-session face-to-face group intervention that is based on motivational interviewing (Miller \& Rollnick, 2013) and relapse prevention (Marlatt \& Donovan, 2005) and addresses the reduction of disorder-specific risk behaviors, i.e. alcohol use for AUD and SZ+AUD and medication non-adherence for SZ. After discharge, a 4-week ecological momentary intervention (EMI) supports participants to maintain abstinence from risk behaviors and to strengthen coping in high-risk situations relying on mental contrasting and implementation intentions (Oettingen \& Gollwitzer, 2011). Participants will be assessed in fMRI and behavioral measurements and by self-report pre and post interventional phase, furthermore they participate in an ecological momentary assessment during the post-discharge phase which assesses risk behaviors, high-risk situations and risk perception in real life contexts.

02

Conditions studied

  • Alcohol Use Disorder (AUD)
  • Schizophrenia and Related Disorders
03

In context

Alcoholism

1,674 studies on the registry are indexed under Alcoholism; 331 are open to participants now.

This study's planned enrollment of 240 is above the median of 88 across 1,428 interventional studies indexed under Alcoholism.

Browse Alcoholism studies →

Lead sponsor

University of Konstanz is the lead sponsor of 51 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • for patient groups: fulfilling the diagnostic criteria for AUD or SZ or both

Exclusion criteria

Exclusion Criteria:

for patient groups and healthy control group:

  • no sufficient command of German language
  • neurological disorder for patient groups:
  • acute psychotic episode
  • acute suicidality or not distanced from self-harming behaviors
  • other substance use disorder (exception: nicotine and caffeine use disorders) for healthy control group:
  • absence of any psychiatric diagnosis (exception: nicotine and caffeine use disorders)
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    AUD Intervention

    Risk behavior specific intervention, targeting alcohol drinking

    Behavioral: Cognitive Behavioral Therapy for reducing risk behaviors

  • Active comparator
    AUD Control

    Non-risk behavior specific intervention, targeting cognitive exercises

    Behavioral: Cognitive Behavioral Therapy for increasing non-risk behaviors

  • Experimental
    AUD & SZ Intervention

    Risk behavior specific intervention, targeting alcohol drinking

    Behavioral: Cognitive Behavioral Therapy for reducing risk behaviors

  • Active comparator
    AUD & SZ Control

    Non-risk behavior specific intervention, targeting cognitive exercises

    Behavioral: Cognitive Behavioral Therapy for increasing non-risk behaviors

  • Experimental
    SZ Intervention

    Risk behavior specific intervention, targeting medication non-adherence

    Behavioral: Cognitive Behavioral Therapy for reducing risk behaviors

  • Active comparator
    SZ Control

    Non-risk behavior specific intervention, targeting cognitive exercises

    Behavioral: Cognitive Behavioral Therapy for increasing non-risk behaviors

  • No intervention
    HC Control

    Healthy control subjects will participate in fMRI assessments only

Interventions

  • BehavioralCognitive Behavioral Therapy for reducing risk behaviors

    Cognitive Behavioral Therapy to reduce risk behaviors and increase risk perception that combines a standardised face-to-face group therapy before discharge from in-patient treatment and a standardised ecological momentary intervention delivered by mobile phones during the four weeks after discharge. For SZ the target risk behavior is medication non-adherence and for AUD and AUD \& SZ it is alcohol use.

  • BehavioralCognitive Behavioral Therapy for increasing non-risk behaviors

    Cognitive Behavioral Therapy to increase non-risk behaviors that combines a standardised face-to-face group therapy before discharge from in-patient treatment and a standardised ecological momentary intervention delivered by mobile phones during the four weeks after discharge. In this control intervention for patient groups the target behavior is cognitive exercises.

06

What researchers measure

Primary outcomes

  1. Change of Nucleus Accumbens activation and connectivity during risky decision making

    Change of fMRI signal (BOLD) in Balloon Analogue Risk Task

    Time frame: 6 weeks

  2. Engagement in risk behaviors

    Alcohol drinking (for AUD and AUD+SZ) and medication non-adherence (for SZ) as recorded by ecological momentary assessment (EMA)

    Time frame: 4 weeks

Secondary outcomes

  1. Risk reappraisal

    Change of risk perception after critical event depending on the outcome of the critical event (engaging is risk behavior or not) as defined by Klepper et al. (2017)

    Time frame: 4 weeks

  2. Activation of amygdala, STS, mPFC and insula during risk evaluation

    fMRI signal (BOLD) in a trustworthiness task

    Time frame: 6 weeks

07

Study locations

1 of 1 sites recruiting
  • University of Konstanz, Research Ward
    Konstanz, 78464, Germany
    Recruiting
08

References and documents

Publications

  • Klepper S, Odenwald M, Rosner S, Senn S, Menning H, Pereyra-Kroll D, Rockstroh B. Experience-Induced Change of Alcohol-Related Risk Perception in Patients with Alcohol Use Disorders. Front Psychol. 2017 Nov 13;8:1967. doi: 10.3389/fpsyg.2017.01967. eCollection 2017. PubMed 29180975 ↗
  • Gollwitzer P, Oettingen G (2011). Planning promotes goal striving. In: KD Vohs, RF Baumeister (Eds.), Handbook of Self-Regulation: Research, Theory, and Applications (2nd edition, chapter 9, pp. 162 - 184). The Guilford Press.
  • Marlatt GA, Donovan, DM. Relapse Prevention. 2nd edition. The Guilford Press.
  • Miller R, Rollnick S (2013) Motivational Interviewing. 3rd edition. The Guilford Press.

Individual participant data

Plan to share: Yes — Data will be made available upon request ensuring the data protection laws are fulfilled

Time frame: 6 months after publication

Access criteria: will be defined according to legal requirements

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04985786
Lead sponsor
University of Konstanz
Collaborators
Centre for Psychiatry Reichenau, Germany
Responsible party
Michael Odenwald (Chief Psychologist Research Ward, University of Konstanz) — Principal investigator
First posted
Aug 2, 2021
Start date
Jul 10, 2021
Primary completion
Dec 31, 2022 (estimated)
Completion
Apr 30, 2023 (estimated)
Last update
Aug 11, 2021

Study contacts

Michael Odenwald, Dr.
Contact
michael.odenwald@uni-konstanz.de
+49 7531 884621
Daniela Mier, Prof. Dr.
Contact
daniela.mier@uni-konstanz.de
+49 7531 884672

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion